Page last updated: 2024-12-07

methylumbelliferyl-beta-d-xyloside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Methylumbelliferyl-beta-D-xyloside (MUF-Xyl) is a fluorogenic substrate for xylosidase enzymes, such as β-xylosidase. It is commonly used in research to measure xylosidase activity in various biological samples, including bacteria, fungi, and plant extracts. MUF-Xyl is hydrolyzed by xylosidase enzymes, releasing the fluorescent product methylumbelliferone (MU). The fluorescence intensity of MU is directly proportional to the xylosidase activity. MUF-Xyl has been used in research on the identification and characterization of xylosidases, as well as in the development of assays for the detection and quantification of xylosidases in different biological samples. It is also used in the study of the role of xylosidases in various biological processes, such as the degradation of plant cell walls and the biosynthesis of xylan.'
```

Cross-References

ID SourceID
PubMed CID92229
CHEMBL ID1938471
SCHEMBL ID197177
MeSH IDM0062381

Synonyms (48)

Synonym
4-methylumbelliferyl beta-d-xylopyranoside
7-(beta-d-xylopyranosyloxy)-4-methyl-2h-1-benzopyran-2-one
4-methylumbelliferyl-beta-d-xylopyranoside, beta-xylosidase substrate
4-methylumbelliferyl-beta-d-xyloside
6734-33-4
4-methylumbelliferyl-beta-d-xylopyranoside
4-methyl-7-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxychromen-2-one
AKOS005257904
bdbm50361734
(4-methylumbelliferone)-beta-d-xylopyranoside
einecs 229-784-4
2h-1-benzopyran-2-one, 4-methyl-7-(beta-d-xylopyranosyloxy)-
766n8850ja ,
methylumbelliferyl-beta-d-xyloside
4-methylumbelliferyl beta-xyloside
4-methyl-7-(beta-d-xylopyranosyloxy)-2h-1-benzopyran-2-one
unii-766n8850ja
4-methylumbelliferyl-beta-xyloside
4-methylumbelliferyl beta-d-xyloside
CHEMBL1938471 ,
S12045
AKOS015899834
2h-1-benzopyran-2-one,4-methyl-7-(b-d-xylopyranosyloxy)-
SCHEMBL197177
4-methylumbelliferyl b-d-xylopyranoside
4-methyl-7-(.beta.-d-xylopyranosyloxy)-2h-1-benzopyran-2-one
4-methylumbelliferyl .beta.-d-xylopyranoside, (-)-
coumarin, 4-methyl-7-(.beta.-d-xylopyranosyloxy)-
4-methylumbelliferyl .beta.-d-xylopyranoside
4-methylumbelliferone-.beta.-d-xyloside
DTXSID10217687
mfcd00037607
4-methylumbelliferyl i(2)-d-xylopyranoside
2h-1-benzopyran-2-one, 4-methyl-7-(.beta.-d-xylopyranosyloxy)-
AS-70369
4-methyl-7-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-2h-chromen-2-one
4-methylumbelliferyl-|a-d-xylopyranoside
4-methyl-7-((2s,3r,4s,5r)-3,4,5-trihydroxytetrahydro-2h-pyran-2-yloxy)-2h-chromen-2-one
Q27894530
4-methyl-7-(((2s,3r,4s,5r)-3,4,5-trihydroxytetrahydro-2h-pyran-2-yl)oxy)-2h-chromen-2-one
4'-methylumbelliferyl-b-d-xylose
4-methylumbelliferylb-d-xylopyranoside
boc-(s)-3-amino-4-(2-thienyl)butanoicacid
AMY41722
2h-1-benzopyran-2-one, 4-methyl-7-(b-d-xylopyranosyloxy)-
4-methylumbelliferyl- beta -d-xylopyranoside
HY-137824
PD171160
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Ki0.10500.00021.10439.9000AID641826
Carbonic anhydrase 1Homo sapiens (human)Ki3.40000.00001.372610.0000AID641823
Carbonic anhydrase 2Homo sapiens (human)Ki100.00000.00000.72369.9200AID641824
Carbonic anhydrase 9Homo sapiens (human)Ki0.35000.00010.78749.9000AID641825
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID641824Inhibition of human full-length cytosolic CA2 after 6 hrs by stopped flow CO2 hydration assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.
AID641825Inhibition of human recombinant CA9 after 6 hrs by stopped flow CO2 hydration assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.
AID641826Inhibition of human recombinant CA12 after 6 hrs by stopped flow CO2 hydration assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.
AID641823Inhibition of human full-length cytosolic CA1 after 6 hrs by stopped flow CO2 hydration assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (29.27)18.7374
1990's20 (48.78)18.2507
2000's5 (12.20)29.6817
2010's4 (9.76)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.66 (24.57)
Research Supply Index3.78 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other43 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]